To enhance NK cell expansion and cytotoxicity, modified dendritic cell-derived exosomes activated NK cells could improve anti-CML effects via NKG2D/NKG2D-L pathway (167). The gene discussed is KLRK1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.